Natalizumab and primary central nervous system lymphoma revisited
β Scribed by Andreas Schweikert; Muna Hoshi; Bernhard Hemmer; Achim Berthele
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 95 KB
- Volume
- 69
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A 40βyearβold man with relapsingβremitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th deca
A 51-year-old Chinese man underwent an orthotopic liver transplantation for liver carcinoma that developed in the setting of cirrhosis linked to HBV infection. The Image 1. Image 2. Image 3.
Primary central nervous system lymphoma (PCNSL) is a rare neoplasm, but it is occurring with increased frequency even among apparently immunocompetent patients. Although secondary malignancies frequently involve the lymphoreticular system, PCNSL has been reported as a second neoplasm only once previ